Despite the limitations of this retrospective cohort study, it provides valuable insight into the impact of RAS inhibitors and SGLT2 inhibitors, alone or in combination, on ESKD incidence and all-cause mortality in patients with diabetes and hypertension. Here, SLC5A2 is linked to Hypertension.